- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05731544
Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)
February 9, 2024 updated by: Biomea Fusion Inc.
A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, PK, and PD of BMF-219, an Oral Covalent Menin Inhibitor, in Healthy Adults and Adults With T2D
A Phase 1/ 2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMF-219, an Oral Covalent Menin Inhibitor, in Healthy Adult Subjects and in Adult Subjects with Type 2 Diabetes Mellitus.
Study Overview
Detailed Description
This is a Phase 1/ 2 study that will examine the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple dose levels of BMF-219, an orally bioavailable selective covalent inhibitor of menin, in healthy subjects and in subjects with T2D.
This study will assess the effect of BMF-219 as single ascending dose (SAD) and multiple ascending dose (MAD).
Study Type
Interventional
Enrollment (Estimated)
414
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sanchita Mourya, MD
- Phone Number: 1-844-245-0490
- Email: clinicaltrials@biomeafusion.com
Study Contact Backup
- Name: Rima Sakhapara
- Phone Number: 1-844-245-0490
- Email: clinicaltrials@biomeafusion.com
Study Locations
-
-
-
Toronto, Canada, M9L 3A2
- Active, not recruiting
- BioPharma Services Inc.
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G2E1
- Recruiting
- Alberta Diabetes Institute Clinical Research Unit
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Y 3W2
- Recruiting
- BC Diabetes
-
-
Ontario
-
Brampton, Ontario, Canada, L6S 0C6
- Recruiting
- Centricity Research Brampton Endocrinology
-
Toronto, Ontario, Canada, M4G 3E8
- Recruiting
- Centricity Research LMC
-
-
-
-
Arizona
-
Tempe, Arizona, United States, 85282
- Active, not recruiting
- Voyage Medical Services
-
-
California
-
Canoga Park, California, United States, 91303
- Recruiting
- Hope Clinical Research
-
Fountain Valley, California, United States, 92708
- Recruiting
- Ark Clinical Research, LLC
-
Huntington Park, California, United States, 90255
- Recruiting
- Velocity Clinical Research
-
La Mesa, California, United States, 91942
- Recruiting
- Velocity Clinical Research
-
Lincoln, California, United States, 95648
- Recruiting
- Clinical Trials Research
-
Long Beach, California, United States, 90815
- Recruiting
- Ark Clinical Research
-
Montclair, California, United States, 91763
- Recruiting
- Catalina Research Institute, LLC
-
San Bernardino, California, United States, 92404
- Recruiting
- Metro Clinical Trials
-
-
Florida
-
Edgewater, Florida, United States, 32132
- Recruiting
- Velocity Clinical Research
-
Fort Myers, Florida, United States, 33907
- Recruiting
- Southwest General Healthcare Center
-
Hialeah, Florida, United States, 33010
- Recruiting
- G+C Research Group
-
Homestead, Florida, United States, 33032
- Active, not recruiting
- Sunbright Health Research Centers
-
Hudson, Florida, United States, 24667
- Recruiting
- Diabetes Care Center
-
Miami, Florida, United States, 33155
- Recruiting
- Avantis Clinical Research
-
Miami, Florida, United States, 33176
- Recruiting
- Entrust Clinical Research
-
Miami Lakes, Florida, United States, 33014
- Recruiting
- Panax Clinical Research
-
Orlando, Florida, United States, 32808
- Recruiting
- Omega Research Orlando
-
-
Georgia
-
Cordele, Georgia, United States, 31015
- Recruiting
- David Kactaradze MD, Inc
-
Johns Creek, Georgia, United States, 30005
- Active, not recruiting
- Georgia Clinic
-
Savannah, Georgia, United States, 31406
- Recruiting
- Privia Medical Group
-
-
Illinois
-
Chicago, Illinois, United States, 60607
- Recruiting
- Cedar Crosse Research Center
-
-
Louisiana
-
Metairie, Louisiana, United States, 70006
- Recruiting
- Velocity Clinical Research
-
-
Michigan
-
Canton, Michigan, United States, 48188
- Active, not recruiting
- Voyage Medical Services
-
-
Missouri
-
Saint Louis, Missouri, United States, 63117
- Recruiting
- IMA Clinical Research St. Louis
-
-
Nevada
-
Las Vegas, Nevada, United States, 89119
- Recruiting
- Santa Rosa Medical Centers of Nevada
-
-
New York
-
Brooklyn, New York, United States, 11220
- Recruiting
- Omera Health
-
New York, New York, United States, 10036
- Recruiting
- IMA Clinical Research Manhattan
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28210
- Recruiting
- Tyron Medical Partners
-
Shelby, North Carolina, United States, 28150
- Recruiting
- Carolina Research Center
-
Winston-Salem, North Carolina, United States, 27104
- Recruiting
- Wake Forest Health Network, LLC, Medical Plaza
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Recruiting
- Diabetes and Endocrinology Associates of Stark County
-
Columbus, Ohio, United States, 43213
- Recruiting
- Centricity Research CPU-Ohio
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37404
- Recruiting
- Chattanooga Research & Medicine
-
Elizabethton, Tennessee, United States, 37643
- Recruiting
- Medical Care, LLC
-
-
Texas
-
Austin, Texas, United States, 78745
- Recruiting
- IMA Clinical Research
-
Dallas, Texas, United States, 75230
- Recruiting
- Zenos Clinical Research
-
Dallas, Texas, United States, 75230
- Recruiting
- Velocity Clinical Research
-
Houston, Texas, United States, 77036
- Recruiting
- Synergy Groups Medical LLC
-
Houston, Texas, United States, 77061
- Recruiting
- Synergy Group Medical
-
Missouri City, Texas, United States, 77459
- Recruiting
- Synergy Group Medical
-
San Antonio, Texas, United States, 78229
- Recruiting
- Clinical Trials of Texas, LLC
-
Sugar Land, Texas, United States, 77478
- Recruiting
- Simcare Medical Research
-
Waco, Texas, United States, 76710
- Recruiting
- Velocity Clinical Research
-
-
Utah
-
Jordan, Utah, United States, 84088
- Recruiting
- Velocity Clinical Research
-
-
Virginia
-
Manassas, Virginia, United States, 20110
- Recruiting
- Manassas Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
Healthy Subject Inclusion Criteria:
- Males or females, age ≥18 and ≤65 years.
- BMI ≥18 and ≤35 kg/m2.
- Subjects are healthy on the basis of their medical history, physical examination, ECG, and routine laboratory data.
- Females are to be not pregnant, non-lactating. Females can be postmenopausal. Females of childbearing potential must have a negative pregnancy test at screening and be willing to have additional pregnancy tests during the study.
- All subjects must be willing and able to provide written, signed informed consent and be willing and able to comply with all study procedures and tests.
Subjects with T2D: (MAD Cohorts) Inclusion Criteria:
- Males or females, age ≥18 and ≤65 years.
- Diagnosed with T2D within the last 15 years.
- Treated with lifestyle management with or without at the most 3 anti-diabetic medications with a stable dose for at least 2 months prior to screening. If on metformin, the stable dose should be at least 500mg/day.
- HbA1c ≥7.0% and ≤10.5%.
- BMI ≥25 and ≤40 kg/m2.
- Females are to be not pregnant, non-lactating. Females can be postmenopausal. Females of childbearing potential must have a negative pregnancy test at screening and be willing to have additional pregnancy tests during the study.
- All Subjects must be willing and able to provide written, signed informed consent and be willing and able to comply with all study procedures and tests.
Subjects with T2D: (Expansion Cohort) Inclusion Criteria:
- Males or females, age ≥18 and ≤65 years.
- Diagnosed with T2D within the last 7 years.
- Treated with lifestyle management with or without at the most 3 anti-diabetic medications with a stable dose for at least 2 months prior to screening. If on metformin, the stable dose should be at least 500mg/day.
- HbA1c ≥7.0% and ≤10.5%.
- BMI ≥25 and ≤40 kg/m2.
- Females are to be not pregnant, non-lactating. Females can be postmenopausal. Females of childbearing potential must have a negative pregnancy test at screening and be willing to have additional pregnancy tests during the study.
- All Subjects must be willing and able to provide written, signed informed consent and be willing and able to comply with all study procedures and tests.
Exclusion Criteria:
Healthy Subject Exclusion Criteria:
- Evidence or history of any clinically significant disease or malignancy.
- Mean QTcF ≥ 440 msec on triplicate ECGs. Use of medications known to significantly prolong the QT or QTcF interval.
- History of hypertension or untreated hypertension (sitting systolic blood pressure (BP) ≥140 and diastolic BP ≥90 mm Hg).
- Known self or family history (first-degree relative) of multiple endocrine neoplasia Type 1.
- History of stomach or intestinal surgery or resection (except appendectomy, hernia repair, and/or cholecystectomy).
- A history or evidence of human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) infection at screening or active COVID-19 infection on screening. A COVID-19 infection requiring hospitalization within the past 30 days prior to the screening visit is not allowed.
- Use of any live vaccines against infectious diseases within 30 days of initiation of investigational product.
- Current smoker of more than 5 cigarettes per day.
- Use of proton pump inhibitors is prohibited. Antacids are permitted but must be given a minimum of 2 hrs before or 2 hrs after administration of study drug. Subjects receiving PPIs who switch to H2receptor antagonists are eligible for enrollment in the study.
- Excessive use (>8 cups/day) of coffee, tea, soda.
- Receiving an investigational intervention or having participated in another clinical trial within 30 days.
- Currently dieting (formal weight loss program) and/or are currently using or have used within 2 months of screening any drugs for weight management.
- Received prior menin inhibitor treatment.
Subjects with T2D (MAD Cohorts) Exclusion Criteria:
- Type 1 Diabetes Mellitus or a secondary form of diabetes or any prior history of diabetic ketoacidosis.
- Have had recurrence (≥2 episodes) of severe hypoglycemia (defined by the occurrence of neuroglycopenic symptoms requiring the assistance of another person for recovery) within the last 6 months prior to screening or, has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms as judged by the Investigator.
- Known self or family history (first-degree relative) of multiple endocrine neoplasia Type 1.
- Use of anti-diabetes medications (sulfonylureas, insulin, dipeptidyl peptidase-IV inhibitor [DPP-4I] [linagliptin and saxagliptin only] thiazolidinediones) within last 2 months prior to screening.
- Fasting plasma glucose ≥255 mg/dL.
- Fasting C-peptide <0.8 ng/ml.
- Fasting insulin >55 μIU/mL.
- Mean QTcF ≥450 ms. Use of medications known to significantly prolong the QT or QTc interval.
- Fasting triglyceride ≥500 mg/dL.
- Have an eGFR <60 mL/min/1.73 Equation at screening.
- AST ALT > 1.5 × ULN, bilirubin > 1.5 × ULN. Isolated GGT elevation >2.5 ULN without > 1.5 x ULN AST, ALT and/or total bilirubin but with a history of abnormal LFTs in the last 6 months or a medical history of a liver disorder should be excluded.
- History of acute or chronic pancreatitis.
- Serum lipase and/or amylase above 1.5 x ULN.
- Active hepatitis B virus (HBV) or active hepatitis C virus (HCV) at screening. Known positive test, if any, prior to screening or history of human immunodeficiency virus (HIV). An active COVID-19 infection at screening. A COVID-19 infection requiring hospitalization (or release from the hospital) within the past 30 days prior to the screening visit.
- Use of any live vaccines against infectious diseases within 30 days of initiation of investigational product.
- Subjects with positive drug screen (except marijuana [tetrahydrocannabinol (THC)] during screening.
- TSH >6 mIU/L or <0.4 mIU/L (on stable thyroid replacement dose for 3 months prior to screening).
- Severe uncontrolled treated or untreated hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg).
- Diagnosis of, or treatment for, any cancer within the last 2 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ, melanoma in situ) treated with potentially curative therapy.
- History of stomach or intestinal surgery or resection and/or gastroparesis (except that appendectomy, hernia repair, and/or cholecystectomy will be allowed).
- History of cirrhosis.
- Current smokers of more than 3 cigarettes per day.
- Currently dieting (formal weight loss program) and/or are currently using or have used within 2 months of screening any drugs for weight management.
- Use of Proton pump inhibitors is prohibited. Subjects receiving PPIs who switch to H2-receptor antagonists are eligible for enrollment in the study.
- History of any illness, underlying medical condition or unstable medical or psychological condition (including drug or alcohol abuse) that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering study drug to the subject.
Subjects with T2D (Expansion Cohort) Exclusion Criteria:
- Type 1 Diabetes Mellitus or a secondary form of diabetes.
- Prior history of diabetic ketoacidosis or hyperosmolar coma.
- History of severe hypoglycemia (defined by the occurrence of neuroglycopenic symptoms requiring the assistance of another person for recovery) within the last 6 months prior to screening or, has a history of hypoglycemia unawareness.
- Known self or family history (first-degree relative) of multiple endocrine neoplasia Type 1 (MEN1).
- Use of any of the following anti-diabetes medications within 2 months prior to screening: sulfonylureas, insulin, and the dipeptidyl peptidase-4 inhibitors (DPP4i) linagliptin and saxagliptin (sitagliptin and other DPP4i allowed) thiazolidinones [TZD]) within last 2 months prior to screening.
- Fasting plasma glucose ≥255 mg/dL.
- Fasting C-peptide <0.8 ng/ml.
- Fasting insulin >55 μIU/mL.
- Mean QTcF interval >450 ms on triplicate ECGs. Use of prescription or over-the-counter medications known to significantly prolong the QT or QTc interval is excluded.
- Fasting triglyceride ≥500 mg/dL.
- eGFR<60 mL/min/1.73.
- (AST) or (ALT) >1.5 × ULN, Total bilirubin >1.5 × ULN at screening.
- History of acute or chronic pancreatitis.
- Serum lipase and/or amylase above 1.5 x ULN.
- Active hepatitis B (HBV) or active hepatitis C virus (HCV) at screening. Known positive test or history of human immunodeficiency virus (HIV). An active COVID-19 infection at screening. A COVID-19 infection requiring hospitalization (or release from the hospital) within the past 30 days prior to the screening visit.
- Subjects with positive drug screen (except marijuana [tetrahydrocannabinol (THC)]) during screening.
- TSH >6 mIU/L or <0.4 mIU/L (on stable thyroid replacement dose for 3 months prior to screening).
- Severe uncontrolled treated or untreated hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg).
- Diagnosis of, or treatment for, any cancer within the last 2 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ, melanoma in situ) treated with potentially curative therapy.
- History of stomach or intestinal surgery or resection and/or gastroparesis.
- History of cirrhosis.
- Current smokers of more than 5 cigarettes per day.
- Currently dieting (formal weight loss program) and/or are currently using or have used within 2 months of screening any drugs for weight management.
- Use of Proton pump inhibitors is prohibited. Subjects receiving PPIs who switch to H2-receptor antagonists are eligible for enrollment in the study.
- Any known or suspected allergy to trial product, similar compounds or excipients. medical or psychological condition (including drug or alcohol abuse) or historical abnormal laboratory values that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering study drug to the subject.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1 SAD Cohorts
Phase 1 SAD Cohorts with healthy adults randomized 3:1 receiving BMF-219 or placebo.
|
Investigational Product
|
Experimental: Phase 1 single dose food effect sub-study
Phase 1 single dose food effect sub-study with healthy adults randomized 1:1:1:1:1:1 receiving BMF-219 or placebo fasted, with a low-fat meal, and with a high fat meal.
|
Investigational Product
|
Experimental: Phase 1 single dose tablet PK sub-study
Phase 1 single dose x3 PK tablet open-label sub-study with healthy adults randomized 1:1 receiving BMF-219 or placebo fasted, with a low-fat meal, and with a high-fat meal).
|
Investigational Product
|
Experimental: Phase 2 MAD Cohorts
Phase 2 MAD Cohorts with healthy adults (MAD1) or adults with T2D (MAD 2-8) randomized 3:1 receiving BMF-219 or placebo.
|
Investigational Product
|
Experimental: Phase 2 Expansion Cohort
Phase 2 Expansion Cohort adults with T2D randomized 3:1 ratio receiving BMF-219 or placebo.
|
Investigational Product
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety Assessments
Time Frame: 52 weeks
|
Assessed by treatment emergent adverse events.(TEAEs),
drug discontinuation due to TEAEs, serious adverse events, clinically significant laboratory, vital, and ECG evaluations.
|
52 weeks
|
Pharmacokinetics Assessments
Time Frame: 12 weeks
|
Assessed by effect of fed conditions on serial and sparse pharmacokinetic data.
|
12 weeks
|
Change in HbA1c
Time Frame: 12 weeks.
|
Assess the change in HbA1c from baseline to week 12.
|
12 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the effects of BMF-219 on glycemic parameters in subjects with T2D.
Time Frame: 18 months
|
Assess changes in plasma glucose, c-peptide, and insulin at different timepoints both fasted and in response to OGTT.
|
18 months
|
To determine the impact of multiple ascending doses of BMF-219 on beta-cell function in subjects with T2D.
Time Frame: 18 months
|
Descriptive summaries of homeostatic model assessment beta-cell function %beta and insulin resistance (HOMA-B and HOMA- IR).
|
18 months
|
To assess the effect on HbA1c
Time Frame: 12 Months
|
Proportion of subjects achieving an HbA1c < 7% at Week 12.
|
12 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Stephen Morris, MD, Biomea Fusion Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 17, 2022
Primary Completion (Estimated)
July 1, 2024
Study Completion (Estimated)
May 1, 2025
Study Registration Dates
First Submitted
December 26, 2022
First Submitted That Met QC Criteria
February 7, 2023
First Posted (Actual)
February 16, 2023
Study Record Updates
Last Update Posted (Actual)
February 13, 2024
Last Update Submitted That Met QC Criteria
February 9, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- COVALENT-111
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Diabetes Free, Inc.Not yet recruitingDiabetes Mellitus Type 2 - Insulin-Treated
Clinical Trials on BMF-219
-
Biomea Fusion Inc.RecruitingType 1 Diabetes MellitusUnited States, Canada
-
Biomea Fusion Inc.RecruitingColorectal Cancer | Pancreatic Cancer | NSCLC | Non Small Cell Lung Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | CRC | KRAS Mutation-Related Tumors | Relapsed Cancer | Refractory Cancer | Stage IV Non-small Cell Lung Cancer | Stage IV Colorectal Cancer | Stage III Non-small Cell Lung Cancer | Stage III NSCLC and other conditionsUnited States, Korea, Republic of
-
Biomea Fusion Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | Acute Myeloid Leukemia | Cancer | Progression | Multiple Myeloma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Plasma Cell Myeloma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Refractory | Myeloma, Plasma-Cell | Myelomatosis | Acute Mixed-Phenotype...United States, Spain, Netherlands, Greece, Italy
-
Rapport Therapeutics Inc.Not yet recruiting
-
Biomea Fusion Inc.RecruitingAcute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Mixed-Phenotype LeukemiaUnited States
-
Afferent Pharmaceuticals, Inc.CompletedOsteoarthritis of the KneeUnited States
-
Afferent Pharmaceuticals, Inc.CompletedIdiopathic Pulmonary FibrosisUnited States
-
Afferent Pharmaceuticals, Inc.CompletedRefractory Chronic CoughUnited Kingdom
-
Afferent Pharmaceuticals, Inc.Completed
-
Afferent Pharmaceuticals, Inc.CompletedCough | Idiopathic Pulmonary Fibrosis